FDA removes partial hold on Telcyta clinical development

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

A phase 1b evaluating NXP800 in platinum-resistant ARID1A-mutated ovarian cancer is open for enrollment in the United Kingdom and the United States.

ONCOLOGY spoke with Eric Ko, MD, PhD, who recently published a review article with his colleagues on strategies for combining radiation therapy with immunotherapy for the treatment of non–small-cell lung cancer.

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.

Rian M. Hasson Charles, MD, MPH, FACS, has a first-of-its-kind role at Brigham Women’s Hospital that will focus on health equity.